You just read:

Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need

News provided by

Regeneron Pharmaceuticals, Inc.

Mar 10, 2018, 09:02 EST